Has Jonathan Van Ness confirmed using Ozempic, Wegovy, or any GLP-1 medication?

No. As of this writing, JVN has not publicly confirmed using any GLP-1 receptor agonist. All claims linking JVN to these medications are based on social media speculation, not verified statements.

How much weight do people typically regain after stopping semaglutide?

The STEP 1 extension data showed participants regained approximately two-thirds of their lost weight within one year of discontinuation. Individual results vary based on lifestyle factors and concurrent interventions.

Is it safe to take GLP-1 medications indefinitely?

Current evidence supports long-term use. The SELECT trial followed patients on semaglutide for nearly four years and found sustained cardiovascular benefits with a manageable side-effect profile. Ongoing monitoring for gastrointestinal, pancreatic, and gallbladder issues is recommended.

Can diet and exercise prevent weight regain after stopping a GLP-1 drug?

Lifestyle interventions can reduce the magnitude of regain but are unlikely to prevent it entirely, given the hormonal and metabolic adaptations that persist after weight loss. Higher protein intake, resistance training, and behavioral support show the strongest evidence for partial maintenance.

Why do obesity medicine specialists call obesity a chronic disease?

Because the biological mechanisms that drive weight regain (hormonal shifts, metabolic adaptation, neurological appetite regulation) persist long after weight is lost. This chronic-disease framing supports the use of long-term pharmacotherapy, much as hypertension or type 2 diabetes require ongoing treatment.

Jonathan Van Ness, Maintenance, and What Happens If You Stop

By HealthRX Medical Team

Published May 25, 2026Updated May 25, 2026Last reviewed May 25, 2026

At a glance

Public record status: Jonathan Van Ness has discussed body acceptance and weight changes in interviews and on social media. No public statement confirms GLP-1 medication use.
Speculation source: Social media commentary about visible physical changes; no credible sourcing beyond audience observation.
Clinical focus of this page: What happens when someone stops a GLP-1 receptor agonist, why weight regain occurs, and what the data says about long-term use versus discontinuation.
HealthRX Medical Team position: Speculating about any individual's private medical decisions is inappropriate. The clinical science around GLP-1 discontinuation, however, is directly relevant to millions of patients weighing these choices right now.

What Jonathan Van Ness Has Actually Said

Jonathan Van Ness has been candid about struggles with body image, self-acceptance, and the pressures of public life. In interviews and on the podcast Getting Curious, JVN has discussed how weight has fluctuated over the years and how the entertainment industry amplifies scrutiny of physical appearance.

None of these public statements reference GLP-1 receptor agonists. JVN has not named semaglutide, tirzepatide, liraglutide, or any branded version of these drugs in any verified public interview, social media post, or on-camera appearance as of this writing.

The speculation connecting JVN to GLP-1 medications originates entirely from social media users observing changes in appearance. The HealthRX Medical Team notes that visible weight changes can result from dozens of factors: shifts in diet, exercise, stress, illness, medication for unrelated conditions, or simply the passage of time. Assuming pharmaceutical intervention based on appearance alone is both clinically unsound and unfair to the individual.

Why GLP-1 Discontinuation Matters Right Now

Regardless of whether any specific public figure uses these medications, the question of what happens after stopping a GLP-1 agonist is one of the most pressing in obesity medicine today. Millions of prescriptions have been written for semaglutide and tirzepatide since their approvals, and a significant share of patients will eventually discontinue treatment due to cost, side effects, insurance changes, supply disruptions, or personal preference.

The STEP 1 trial extension data, published in Diabetes, Obesity and Metabolism, showed that participants who discontinued semaglutide 2.4 mg regained approximately two-thirds of their lost weight within one year of stopping. Cardiometabolic improvements in blood pressure, lipid levels, and HbA1c also reversed substantially. The SURMOUNT-4 trial for tirzepatide showed a similar pattern: participants switched to placebo after 36 weeks of treatment regained roughly half the weight they had lost over the subsequent 52 weeks.

These findings are not surprising from a physiological standpoint. GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, which slows gastric emptying, reduces appetite signaling in the hypothalamus, and improves insulin sensitivity. When the drug is removed, these mechanisms return to their pre-treatment baseline. The body's weight-defense systems, including changes in leptin, ghrelin, and energy expenditure that resist sustained weight loss, reassert themselves.

The Biology Behind Rebound Weight Gain

Weight regain after GLP-1 discontinuation is not a failure of willpower. Research published in The New England Journal of Medicine has demonstrated that the hormonal adaptations to weight loss persist for at least 12 months after the weight is lost. Levels of appetite-stimulating hormones like ghrelin increase. Levels of satiety hormones like peptide YY and GLP-1 (the body's own version) decrease. Resting metabolic rate drops below what would be predicted for the new body weight, a phenomenon sometimes called metabolic adaptation.

GLP-1 receptor agonists essentially override these compensatory signals while active. Discontinuation removes that override. The result is a predictable increase in hunger, a reduction in satiety after meals, and a metabolic environment that favors fat regain.

The HealthRX Medical Team emphasizes that this biological reality applies to everyone, not just public figures. It is why leading obesity-medicine organizations, including the Obesity Medicine Association and the American Association of Clinical Endocrinology, increasingly frame obesity as a chronic disease requiring long-term treatment rather than a short-term condition amenable to a finite course of medication.

What the Evidence Says About Long-Term GLP-1 Use

For patients who continue GLP-1 therapy indefinitely, the data is encouraging. The SELECT trial demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% over a median follow-up of 39.8 months in adults with overweight or obesity and established cardiovascular disease. This cardiovascular benefit is independent of the degree of weight loss and supports ongoing treatment.

Long-term safety data from semaglutide trials extending beyond two years show a side-effect profile dominated by gastrointestinal symptoms: nausea (typically worst in the first 4 to 8 weeks and then declining), diarrhea, constipation, and occasional vomiting. Rates of more serious adverse events, including pancreatitis and gallbladder disease, are low but nonzero and warrant monitoring.

Tirzepatide, a dual GIP/GLP-1 receptor agonist, has shown comparable or greater weight loss in head-to-head positioning studies, with a similar gastrointestinal side-effect profile. Long-term cardiovascular outcome data for tirzepatide in obesity (the SURPASS-CVOT program) are still maturing.

Maintenance Strategies Without Medication

Some patients choose or are forced to discontinue GLP-1 therapy. For these individuals, the clinical literature supports several evidence-based approaches to minimize weight regain:

Structured dietary patterns. A meta-analysis in The BMJ found that higher protein intake (1.2 to 1.6 g/kg/day) during weight maintenance helps preserve lean mass and sustain satiety. Mediterranean-style eating patterns have the strongest long-term adherence data.

Resistance training. Preserving or building skeletal muscle mass partially offsets the decline in resting metabolic rate that accompanies weight loss. The American College of Sports Medicine recommends at least two sessions per week targeting major muscle groups.

Behavioral support. The National Weight Control Registry, tracking over 10,000 individuals who have maintained significant weight loss, consistently finds that self-monitoring (weighing, food logging) and regular physical activity are the strongest predictors of maintenance.

Switching medications. Some clinicians transition patients from injectable GLP-1 agonists to oral semaglutide at lower doses, or to older weight-management drugs like phentermine-topiramate or naltrexone-bupropion, as a step-down strategy. Controlled trial data specifically supporting these transitions remains limited.

The HealthRX Medical Team Take

Public speculation about whether Jonathan Van Ness or any other celebrity uses GLP-1 medications reflects a broader cultural discomfort with these drugs. People want to know who is "really" taking them, as though that knowledge validates or invalidates the treatment.

The HealthRX Medical Team views this differently. The relevant question is not whether a specific individual uses semaglutide or tirzepatide. The relevant question is what the evidence says about starting, continuing, and stopping these medications, because those are the decisions real patients face every day.

The discontinuation data is unambiguous: most patients regain a significant portion of lost weight after stopping GLP-1 therapy. This is not a personal failing. It is a predictable consequence of treating a chronic condition with a time-limited intervention. Patients considering GLP-1 medications should enter treatment with realistic expectations about the likely need for long-term use and should discuss exit strategies with their prescribing clinician before starting.

For anyone in the public eye whose body is subject to constant scrutiny, the pressure to explain or justify physical changes is immense. The HealthRX Medical Team's position is straightforward: medical decisions are private, the science is what matters, and the science here says that GLP-1 discontinuation carries real and well-documented metabolic consequences.

Frequently asked questions

›

References

Wilding JPH, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." N Engl J Med. 2021. https://pubmed.ncbi.nlm.nih.gov/33567185/
Jastreboff AM, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." N Engl J Med. 2022. https://pubmed.ncbi.nlm.nih.gov/35658024/
Aronne LJ, et al. "Continued Treatment with Tirzepatide for Maintenance of Weight Reduction (SURMOUNT-4)." JAMA. 2024. https://pubmed.ncbi.nlm.nih.gov/38389052/
Sumithran P, et al. "Long-Term Persistence of Hormonal Adaptations to Weight Loss." N Engl J Med. 2011. https://pubmed.ncbi.nlm.nih.gov/22003520/
Lincoff AM, et al. "Semaglutide and Cardiovascular Outcomes in Obesity (SELECT)." N Engl J Med. 2023. https://pubmed.ncbi.nlm.nih.gov/37952131/
Ge L, et al. "Comparison of Dietary Macronutrient Patterns for Long-Term Weight Management." BMJ. 2020. https://pubmed.ncbi.nlm.nih.gov/32238384/
Greenway FL. "Physiological Adaptations to Weight Loss and Factors Favouring Weight Regain." Int J Obes. 2015. https://pubmed.ncbi.nlm.nih.gov/27136388/
Filippatos TD, et al. "Adverse Effects of GLP-1 Receptor Agonists." Rev Diabet Stud. 2014. https://pubmed.ncbi.nlm.nih.gov/36356082/